» Articles » PMID: 34631557

A Different View for an Old Disease: NEDDylation and Other Ubiquitin-Like Post-Translational Modifications in Chronic Lymphocytic Leukemia

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Oct 11
PMID 34631557
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Despite the enormous amount of molecular data obtained over the years, the molecular etiology of chronic lymphocytic leukemia (CLL) is still largely unknown. All that information has enabled the development of new therapeutic approaches that have improved life expectancy of the patients but are still not curative. We must increase our knowledge of the molecular alterations responsible for the characteristics common to all CLL patients. One of such characteristics is the poor correlation between mRNA and protein expression, that suggests a role of post-translational mechanisms in CLL physiopathology. Drugs targeting these processes have indeed demonstrated an effect either alone or in combination with other aimed at specific pathways. A recent article unveiled an increment in ubiquitin-like modifications in CLL, with many protein members of relevant pathways affected. Interestingly, the inhibition of the NEDD8-activating protein NAE reverted a substantial number of those modifications. The present review gets the scarce data published about the role of NEDDylation in CLL together and establishes connections to what is known from other neoplasias, thus providing a new perspective to the underlying mechanisms in CLL.

Citing Articles

Distinct NF-kB Regulation Favors a Synergic Action of Pevonedistat and Laduviglusib in B-Chronic Lymphocytic Leukemia Cells Ex Vivo.

Arenas V, Castano J, Dominguez J, Yanez L, Pipaon C Cancers (Basel). 2025; 17(3).

PMID: 39941899 PMC: 11816723. DOI: 10.3390/cancers17030533.


Regulation of Pre-mRNA Splicing: Indispensable Role of Post-Translational Modifications of Splicing Factors.

Kretova M, Selicky T, Cipakova I, Cipak L Life (Basel). 2023; 13(3).

PMID: 36983760 PMC: 10053845. DOI: 10.3390/life13030604.


SUMOylation and NEDDylation in Primary and Metastatic Cancers to Bone.

Gomarasca M, Lombardi G, Maroni P Front Cell Dev Biol. 2022; 10:889002.

PMID: 35465332 PMC: 9020829. DOI: 10.3389/fcell.2022.889002.

References
1.
Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

2.
Maleki Y, Alahbakhshi Z, Heidari Z, Moradi M, Rahimi Z, Yari K . NOTCH1, SF3B1, MDM2 and MYD88 mutations in patients with chronic lymphocytic leukemia. Oncol Lett. 2019; 17(4):4016-4023. PMC: 6425375. DOI: 10.3892/ol.2019.10048. View

3.
Speedy H, Beekman R, Chapaprieta V, Orlando G, Law P, Martin-Garcia D . Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics. Nat Commun. 2019; 10(1):3615. PMC: 6689100. DOI: 10.1038/s41467-019-11582-2. View

4.
Best S, Lam V, Liu T, Bruss N, Kittai A, Danilova O . Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells. Leukemia. 2020; 35(1):156-168. PMC: 8288064. DOI: 10.1038/s41375-020-0794-0. View

5.
Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M . Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016; 127(17):2122-30. PMC: 4912011. DOI: 10.1182/blood-2015-07-659144. View